Sales & Earnings In Brief
Schering-Plough looks to emerging markets: As the U.S. economy continues to falter, Schering-Plough is increasingly focusing on emerging markets such as Brazil, China and Russia, CEO Fred Hassan says in an Oct. 21 third-quarter earnings release. He notes 70 percent of S-P's $4.6 billion in third-quarter net sales were outside the U.S. He adds, consumer and animal health account for approximately $758 million and $278 million of sales respectively. Laxative Miralax drove a 2 percent increase in OTC revenues with $31 million in sales - nearly double last year's third-quarter total. This was not enough to offset weak allergy sales with Claritin down 11 percent to $92 million. Other OTC sales slipped 11 percent to $37 million, contributing to a 1 percent fall of overall OTC sales to $160 million. Beyond OTCs, Kenilworth, N.J.-based S-P's net income fell 21 percent to $589 million in the third quarter
More from Archive
More from Pink Sheet
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.